|
Sign In to gain access to subscriptions and/or personal tools.
|
Clinical Trials, Vol. 4, No. 6,
598-610 (2007)
DOI: 10.1177/1740774507084978
Monitoring rare serious adverse events from a new treatment and testing for a difference from historical controls
Michael P. Fay
Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, 6700B Rockledge Drive, Bethesda, MD 20892-7609, USA, mfay{at}niaid.nih.gov
Chiung-Yu Huang
Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, 6700B Rockledge Drive, Bethesda, MD 20892-7609, USA
Nana A. Y. Twum-Danso
The Task Force for Child Survival and Development, 750 Commerce Drive, Suite 400, Decatur, GA 30030, USA
Background We detail the design of a study to monitor the safety of including albendazole to an existing treatment regimen to eliminate lymphatic filariasis. We wish to show that this new regimen does not increase the rate of a rare serious adverse event (SAE) compared to the old regimen. Controlled but small clinical trials have not detected any increase in the SAE using albendazole, and it is known to have added benefits; therefore, it is unethical to randomize patients to the old regimen.
Purpose A sample size for the new regimen is needed to test that the new rate of SAE is noninferior to the historic rate. If the new regimen does have an inferior rate of SAE then we wish to stop the study early. This setup is different from traditional early stopping for efficacy and futility. In that traditional case, the two stopping decisions are relative to the same null hypothesis of equality, while in our setup, we have two different null hypotheses: the noninferiority null and the equality null. When testing the former, we need not stop early if the new regimen appears better because no subjects are receiving the old regimen anymore anyway. When testing the equality of SAE rates, however, we want to stop early if the new regimen has a significantly higher rate of SAE.
Methods We create a design that uses an exact difference in proportions test for testing noninferiority, but calculates maximal sample size based on conditional power which treats the historical rates as true rates. The design allows for early stopping if the new treatment appears inferior with respect to SAE rate but makes no corrections for multiple testing. We explore the properties of this naive design without assuming the historical rates are known.
Results For our example, we show that our naive design strategy bounds the type I error of the noninferiority hypothesis in all cases and bounds it for the equality hypothesis at 0.05, as long as the true SAE rate is <0.00015. The same design has unconditional power for the noninferiority hypothesis greater than the nominal 80% as long as the true SAE rate for both regimens are <0.00025.
Limitations The type I and power results above hold only for our historical sample size of 17 877. We expect similar type I and power properties to hold with studies with SAE rates similar or less (i.e., < 0.00015) and historical sample sizes similar or smaller.
Conclusions Our design for comparing very rare historical SAE rates to SAE rates of a new treatment has large power to conclude noninferiority of the new treatment SAE rate when both rates are equal, but allows early stopping if the new SAE rates are worse. Clinical Trials 2007; 4: 598—610. http://ctj.sagepub.com
References
- Gyapong JO, Kumaraswami V., Biswas G., et al. Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opinion on Pharmacotherapy 2005; 6(2): 179—200.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- World Health Organization. Lympatic filariasis. Weekly Epidemiological Record 2001; 76: 149—54.[Medline]
[Order article via Infotrieve]
- World Health Organization. Onchocerciasis and its Control: Report of a WHO Expert Committee on Onchocerciasis Control. WHO: Geneva. 1995.
- Pinder M. Loa loa a neglected filarial. Parasitology Today 1988; 4: 279—84.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Boussinesq M., Gardon J. Prevalences of Loa loa microfilaremia throughout the area endemic for the infection. Annals of Tropical Medicine & Parasitology 1997; 91: 573—89.
- Thylefors B., Alleman M. Towards the elimination of onchocerciasis. Annals of Tropical Medicine and Parasitology 2006; 100: 733—46.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Horton J., Witt C., Ottesen EA, et al. An analysis of the safety of the single doses, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology 2000; 121: S147—60.
- Awadzi K., Edwards G., Duke BOL, et al. The co-administration of ivermectin and albendazole safety, pharmacokinetics and efficacy against Onchocerca volvulus. Annals of Tropical Medicine & Parasitology 2003; 97: 165—78.
- World Health Organization. Report on active surveillance for adverse events following the use of drug co-administrations in the global programme to eliminate lymphatic filariasis. Weekly Epidemiological Record 2003; 78: 315—7.[Medline]
[Order article via Infotrieve]
- Boussinesq M., Gardon J., Gardon-Wendel N., et al. Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis. American Journal of Tropical Medicine and Hygiene 1998; 58: 461—9.[Abstract]
- Ducorps M., Gardon-Wendel N., Ranque S., et al. Effets secondaires du traitement de la loase hypermicrofilaremique par l ivermectine. Bulletin de la Societe de Pathologie Exotique et de ses Filiales 1995; 88: 105—12.[Medline]
[Order article via Infotrieve]
- Gardon J., Gradon-Wendel N, Demanga-Ngangue, et al. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 1997; 350: 18—22.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Lehmann EL, Romano JP Testing statistical hypotheses, 3rd edition. Springer, New York, 2005.
- Kepner J., Wackerly D. Some observations on the Makuch/Simon approach to sample size determination in clinical trials with historical controls. Communications in Statistics: Simulations 2001; 30: 611—21.[CrossRef]
- Lee JJ, Tseng C-H. Uniform power method for sample size calculation in historical control studies with binary response. Controlled Clinical Trials 2001; 22: 390—400.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Korn EL, Freidlin B. Conditional power calculations for clinical trials with historical controls. Statistics in Medicine 2006; 25: 2922—31.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Chan ISF. Exact tests of equivalence and efficacy with a non-zero lower bound for comparative studies. Statistics in Medicine 1998; 17(12): 1403—13.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Berger RL, Boos DD p- Values maximized over a confidence set of nuisance parameter. Journal of the American Statistical Association 1994; 89: 1012—16.[CrossRef][ISI]
- Cytel Statistical Software. StatXact Procs for SAS Users, User Manual, Version 6. Cytel Software Corporation, Cambridge, MA, 2004.
- Chan ISF, Bohidar NR Exact power and sample size for vaccine efficacy studies. Communications in Statistics - Theory and Methods 1998; 27: 1305—22.[CrossRef][ISI]
- Jennison C., Turnbull BW Group sequential methods with applications to clinical trials. Chapman and Hall/CRC, Washington, DC, 2000.
- O'Brien PC, Fleming TR A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549—56.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Fay MP, Kim H-J., Hachey M. On using truncated sequential probability ratio test boundaries for Monte Carlo implementation of hypothesis tests. (to appear in Journal of Computational and Graphical Statistics, 2007; available at http:/www.3.niaid.nih.gov/about/organization/dcr/BRB/staff/michael.htm ) Accessed October 17, 2007.
- Dragalin V., Fedorov V., Cheuvart B. Statistical approaches to establishing vaccine safety. Statistics in Medicine 2002; 21: 877—93.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Chan ISF. Proving non-inferiority or equivalence of two treatments with dichotomous endpoints using exact methods. Statistical Methods in Medical Research 2003; 12: 37—58.[CrossRef]
- Makuch RW, Simon RM Sample size considerations for non-randomized comparative studies. Journal of Chronic Diseases 1980; 3: 175—81.
- Xiong X., Tan M., Boyett J. A sequential procedure for monitoring clinical trials against historical controls. Statistics in Medicine 2007; 26: 1497—511.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Pocock SJ Group sequential methods in the design and analaysis of clinical trials. Biometrika 1977; 64: 191—9.[Abstract/Free Full Text]
- Lehmann EL Elements of Large-sample Theory. Springer, New York, 1999.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
|
